Skip to content

A clinical evaluation of Siddha medicine Kizhkkaynelli Samoolam Chooranam Maathirai in the management of patients with Type 2 Diabetes Mellitus (Mathumegam).

An Open-label, Exploratory, and Comparative Randomized Controlled Trial to Evaluate the Efficacy and Safety of Siddha Formulation Kizhkkaynelli Samoolam Chooranam Maathirai in the Management of Mathumegam (T2DM) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/111802
Enrollment
39
Registered
2026-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Kizkkaynelli Samoolam Chooranam Maathirai (KNCM): Two KNCM (each tablet has 500 mg) will be given with the required quantity of Luke warm water in the morning, evening, and after food.

Sponsors

Siddha Clinical Research Unit
Lead Sponsor
Department of Medicine Vardhman Mahavir Medical College and Safdarjung Hospital New Delhi
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients who Clinically confirmed T2DM. Patients with HbA1C above 6.5 percentage to 7 percentage Fasting plasma glucose greater than or equal to 126 mg/dl and 2-hour PPPG greater than or equal to 200 mg/dl Patients willing to participate and giving informed consent.

Exclusion criteria

Exclusion criteria: Patients with HbA1C is more than 7 percentage Pregnant and lactating mothers. Patients with other comorbidities such as Type I Diabetes, Hypertension, Bronchial Asthma, Tuberculosis, Renal diseases, Meningitis, Hepatitis, Carcinoma and other major illnesses. Patients with a history of trauma. participants currently undergoing treatment from other systems of medicine.

Design outcomes

Primary

MeasureTime frame
HbA1c level is reduced 1 to 1.5 % will be expected after completion of study which will be measured by before and after blood investigations.Timepoint: before treatment, 90th and 180th day of trial period

Secondary

MeasureTime frame
NIlTimepoint: Nil

Countries

India

Contacts

Public ContactDr R Susila

Siddha Clinical Research Unit

drsusilasiddha@gmail.com9865564621

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026